{"nctId":"NCT02617628","briefTitle":"Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone","startDateStruct":{"date":"2016-01-01","type":"ACTUAL"},"conditions":["Opiate Dependence"],"count":146,"armGroups":[{"label":"Before Re-entry","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: extended release naltrexone"]},{"label":"After Re-entry","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: extended release naltrexone"]}],"interventions":[{"name":"extended release naltrexone","otherNames":["Vivitrol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Opioid dependent with physiological features according to Diagnostic and Statistical Manual of Mental Disorders-5th edition\n* Interested in extended release naltrexone treatment\n* Eligible to have health benefits reinstated\n* Detoxified and able to pass a naloxone challenge (e.g. no withdrawal within 30 minutes after receiving 0.8 mg naloxone I.M. and documented by a score \\<5 on the Clinical Opiate Withdrawal Scale\n* Age 18 or above\n* Not being transferred to serve a longer sentence in a State or Federal prison\n* Provide their address or phone number along with the names and contact information of 3 or more persons likely to know where they can be reached with permission to contact them if unable to be reached in other ways\n* Able to speak and read English and provide informed consent\n* able to correctly answer 9 of 10 study quiz items\n* not pregnant and agree to the use of an acceptable form of birth control\n* can access to NET Steps via car or public or other transportation after reentry\n\nExclusion Criteria:\n\n* Planning to move from the Philadelphia area within the next 6 months\n* Neurological, cardiovascular, renal, hepatic (Alanine aminotransferase, Aspartate aminotransferase or Gamma-glutamyl transpeptidase \\>3 times top limit of normal) or another medical disorder that seriously impairs or makes hazardous ability to participate\n* Active tuberculosis\n* Currently psychotic, homicidal, suicidal\n* Uncontrolled seizure disorder\n* History of allergy to naltrexone, polylactide-co-glycolide, carboxymethylcellulose, or any other components of the diluent\n* Chronic pain for which opioids are needed\n* Sentenced to naltrexone Treatment","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Relapse to Opioid Use in Subjects by Month 3","description":"Proportion (count) without relapse by month 3 post release. At each monthly assessment we determined whether a subject relapsed based on the timeline follow-back (TLFB) and/or urine drug screen results (UDS) and self-reported withdrawal.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Reincarceration","description":"percentage of patients who were reincarcerated","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":74},"commonTop":["injection site reaction","anxiety","headache","depression","toothache"]}}}